AR and Familial prostate cancer: Despite the low number of research articles on the development of therapies targeting the main components of TME compared to that targeting AR signaling (Figure 1a,b), recent studies emphasize the network of cellular and molecular components, which collectively enable prostate cancer to maintain a complex immunosuppressive nature and to develop resistance to immunotherapies [22].